Overall survival by molecular risk and comutated gene categories. (A) Intention-to-treat population. (B) Patients eligible for high-intensity chemotherapy. (C) Dual comutated DNMT3A and NPM1: patients eligible for high-intensity chemotherapy regimens. NE, not estimable.